1. Home /
    2. Altai Protocol Library /
  2. New Indication: Nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS)

New Indication: Nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS)
Study:
  • Prospective, explorative, two-group, non-randomized, phase II trial (NITraSarc)
  • Advanced, previously treated lipo-leiomyosarcoma (Group A: GA) (n=43) and non-L-sarcomas (Group B: GB) (n=49)
  • Early combination cohort (ECC): Trabectedin x2 cycle followed by Nivolumab + Trabectedin and Late combination cohort (LCC): Trabectedin x3 cycle followed by Nivolumab + Trabectedin
Efficacy:
  • mPFS: 5.5 vs 2.3 mos, GA and GB, respectively
  • 6 mos PFS: 47.6% vs. 14.6%, GA and GB, respectively
  • mPFS: 9.8 vs 4.4 mos, LCC and ECC, respectively
  • mOS: 18.7 vs.5.6 mos, GA and GB, respectively
  • mOS: 24.6 vs.13.9 mos, LCC and ECC, respectively
Safety:
  • Grade≥3 Aes: Unspecified

Journal of Clin Oncol 2023 41:16_suppl, 11500-11500

Reichardt P et al. Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).

http://doi.org/10.1200/JCO.2023.41.16_suppl.11500

Reviewed by Elvin CHALABİYEV, MD on JUN 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More